开发用于儿童过敏原免疫治疗的溶解膜-猫眼课题宝

开发用于儿童过敏原免疫治疗的溶解膜

批准号：

8510886

负责人：

Corinne Keet

金额：

$25.14万

依托单位：

JOHNS HOPKINS UNIVERSITY

依托单位国家：

美国

项目类别：

财政年份：

2013

资助国家：

美国

项目状态：

已结题

起止时间：

2013-06-10 至 2015-05-31

来源：

https://reporter.nih.gov/project-details/8510886

关键词：

Absenteeism Address Admission activity Adult Affect Allergen Immunotherapy Allergens Allergic Disease Allergic rhinitis Allergy to peanuts Antigen-Presenting Cells Area Asthma Biomedical Engineering Characteristics Child Childhood Childhood Asthma Chronic Disease Clinic Clinical Trials Collaborations Core Facility Deglutition Developing Countries Development Dictyoptera Disease Dose Drug Delivery Systems Drug Formulations Drug Kinetics Effector Cell Emergency Situation Ensure Europe Excipients Extrinsic asthma FDA approved Face Felis catus Film Food Food Hypersensitivity Goals Grant Hospitals Hypersensitivity Immunology Immunotherapy In Situ Inhalant dose form Injection of therapeutic agent Learning Liquid substance Location Methodology Methods Milk Hypersensitivity Modeling Morbidity - disease rate Oral Oral cavity Oral mucous membrane structure Peanuts - dietary Pharmacy (field)Phase Powder dose form Process Property Research Risk Safety Schools Time Tongue Translating Translations Vaccination Visit design experience flexibility improved liquid formulation novel oral immunotherapy pediatrician prevent public health relevance respiratory sublingual immunotherapy

项目摘要

项目成果

Corinne Keet的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): Allergic diseases constitute the most common chronic diseases of childhood and cause significant morbidity. However, allergen-specific injection immunotherapy, which is not acceptable to many children and may be too risky for some types of allergy, remains the only approved disease modifying treatment for allergic diseases. Sublingual immunotherapy has been shown to be safer for treatment of both food and aeroallergies, but current methods are not optimized for efficacy, safety or practicality, and are not approved for use in the U.S.. A mucoadhesive, dissolving film improves upon current liquid methods of immunotherapy because it (1) prolongs contact between antigen presenting cells and allergen, which is vital for the efficacy of immunotherapy, (2) allows for more flexible dosing, with both higher and lower standardized doses than are currently available, (3) is a more practical method for use in children, requiring little cooperation and, (4) unlike liquids, is not subject to the risk of aspiration. We have developed such a film for use in the treatment of peanut allergy. In this grant, we propose to extend this method to other important allergens for children and explore methods to optimize its use in children. Aim 1 is to develop and refine orally dissolving strips for treatment of cockroach and cat allergies. These allergies are two of the most important contributors to allergic rhinitis and asthma in children, and each present unique challenges and opportunities for design of a film. Aim 2 is to optimize the pharmacokinetics and palatability of a dissolving film by evaluating the effect of different placements in the mouth and, if need be, formulations on persistence of allergen in the mouth and on palatability. This methods developed here have to the potential to address the fundamental problems that currently limit or entirely prevent translation of immunotherapy in children from research settings to the clinic.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文